Loading

Search

:

Nissan Eyes Capital Restructuring in Alliance with Renault, Ghosn Says

  • Category:Driving
YOKOHAMA (Jiji Press) — Nissan Motor Co. Chairman Carlos Ghosn on Tuesday indicated again his intention to review the capital structure of his company’s alliance with France’s Renault SA.

At a general shareholders meeting in Yokohama, Ghosn, also chairman and chief executive officer at Renault, stressed the importance of ensuring the long-term sustainability through such a review.

But he did not get into any detail of the possible capital restructuring, only saying that there are options.

Nissan President Hiroto Saikawa apologized over a scandal in which unqualified workers participated in finished car inspections. The scandal came to light in autumn last year.

“We are very sorry for causing anxiety among shareholders,” he said, pledging to implement measures to prevent any recurrence of such wrongdoing.

As for the relationship with Renault, he expressed his resolve to “maintain each company’s independence and autonomy.”

Renault holds 43.4 percent of Nissan while the Japanese company owns 15 pct of its French partner.

In terms of worldwide vehicle sales, the alliance, also including Mitsubishi Motors Corp., which is under the wing of Nissan, is the second-biggest player after Germany’s Volkswagen AG.

The French government, the biggest shareholder of Renault, is reportedly asking Ghosn to merge Renault and Nissan after allowing Ghosn to stay on as Renault chairman and chief executive officer.

During the day’s meeting, a shareholder asked, “Who took responsibility for the scandal?” criticizing Nissan’s management team.

Ghosn replied that he did not apologize when the scandal broke because Nissan’s boss is CEO Saikawa, defending his response. Ghosn retired as Nissan CEO and president in April last year.

Ghosn said his executive pay in fiscal 2017 fell 30 percent from the previous year to ¥730 million, while that of Saikawa increased nearly 30 percent to ¥500 million.
 
 

Comment(s) Write comment

<a href="https://baclofeninfo.com/">generic baclofen</a>
<a href="https://augmentininfo.com/">buy augmentin online</a>
<a href="https://amitriptylineinfo.com/">amitriptyline low dose weight gain</a>
<a href="https://allopurinolinfo.com/">300 mg allopurinol</a>
<a href="https://aripiprazoleinfo.com/">aripiprazole adverse effects</a>
<a href="https://aspirininfo.com/">aspirin acetaminophen</a>
<a href="https://infoeffexor.com/">effexor generic cost</a>
<a href="https://infocontrave.com/">get contrave now</a>
<a href="https://ezetimibeinfo.com/">ezetimibe prostate cancer</a>
<a href="https://diltiazeminfo.com/">diltiazem and constipation</a>
Hydroxychloroquine has been studied as a potential adjunctive therapy in the management of chronic inflammatory conditions such as chronic obstructive pulmonary disease (COPD) and inflammatory bowel disease (IBD). [url=https://hcqplaquenil.com]hydroxychlor tab 200mg[/url] While preliminary data suggest that it may have anti-inflammatory effects and improve disease outcomes in some patients, further research is needed to establish its role in these conditions and identify patients who may benefit most from treatment.
<a href="https://ddavpinfo.com/">ddavp uses</a>
<a href="https://cozaarinfo.com/">is cozaar a blood thinner</a>
<a href="https://citalopraminfo.com/">citalopram vs escitalopram</a>
<a href="https://ddavpinfo.com/">ddavp duration</a>

Trackback (You need to login.)